Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible.

Pieter SonneveldMaría-Victoria MateosAdrian AlegreThierry FaconCyrille HulinMahmoud HashimTalitha VinckenTobias KampfenkelSarah CoteJianming HeAnnette LamPhilippe Moreau

Published in: EJHaem (2020)

Our analysis supports the continued use of VTd-mod in clinical practice in transplant-eligible NDMM patients.

Keyphrases

newly diagnosed
multiple myeloma
clinical practice
end stage renal disease
chronic kidney disease
ejection fraction
low dose
high dose
prognostic factors
patient reported outcomes
patient reported